<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071379</url>
  </required_header>
  <id_info>
    <org_study_id>Penta BS19</org_study_id>
    <nct_id>NCT04071379</nct_id>
  </id_info>
  <brief_title>Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio速 Vaccine Primed With Recombinant Hepatitis B</brief_title>
  <official_title>Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio速 Vaccine Primed With Recombinant Hepatitis B at Birth Dose (Using Different Source of Hepatitis B), in Indonesian Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) with Pentabio速 vaccine
      Primed with Recombinant Hepatitis B
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) with Pentabio速 vaccine
      Primed with Recombinant Hepatitis B at Birth dose (using different source of Hepatitis B), in
      Indonesian Infants
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects neonates: Randomized, double blind, 2 arms parallel groups, prospective intervention Study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomized, double blind, 2 arms parallel group, prospective intervention study This study will do the lot to lot consistency and will be compared to registered product</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) with new Hepatitis B bulk</measure>
    <time_frame>28 days after immunization</time_frame>
    <description>Percentage of infants with anti-diphtheria titer and anti-tetanus titer &gt; 0.01 IU/ml, anti HbsAg titer &gt; 10 mIU/ml, and anti PRP-T titer &gt; 0.15 ug/ml 28 days after the last injection of DTP/HB/Hib with different source of Hepatitis B bulk vaccine group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describes antibody response to diphtheria toxoid, tetanus toxoid in both group with the evaluation criteria</measure>
    <time_frame>28 days after immunization</time_frame>
    <description>Serological response to diphtheria toxoid, tetanus toxoid: GMT, percentage of infants with titer &gt; 0.01 IU/ml, &gt; 0.1 IU/ml percentage of infants with increasing antibody titer &gt; 4 times and/or percentage of infants with transition of seronegative to seropositive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological response to the pertussis component (agglutinins)</measure>
    <time_frame>28 days after immunization</time_frame>
    <description>Serological response to the pertussis component (agglutinins): GMT, percentage of infants with titer &gt; 40, &gt; 80, &gt; 160 and &gt; 320 (1/dil.), percentage of infants with increasing antibody titer &gt; 4 times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean of anti-HbsAg</measure>
    <time_frame>28 days after immunization</time_frame>
    <description>Geometric mean of anti-HbsAg, percentage of infants with titer &gt; 10mIU/ml, percentage of infants with increasing antibody titer &gt; 4 times and/ or percentage of infants with transition of seronegative to seropositive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological response to Hib/PRP</measure>
    <time_frame>28 days after immunization</time_frame>
    <description>Serological response to Hib/PRP: GMT, percentage of infants with titer &gt;1 ug /ml ; &gt; 0.15 ug /ml percentage of infants with increasing antibody titer &gt; 4 times and/or percentage of infants with transition of seronegative to seropositive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>28 days after immunization</time_frame>
    <description>Comparison of GMT, seroprotection, percentage of subjects with increasing antibody titer &gt; 4 times and/ or percentage of subjects with transition of seronegative to seropositive following primary series of investigational product compare to control.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Immunogenicity</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>HepB + Penta batch 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Hepatitis B + DTP-HB-Hib batch 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hep B + Pentabio (registered)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant Hepatitis B + Pentabio (registered)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Hepatitis B + DTP-HB-Hib</intervention_name>
    <description>1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib</description>
    <arm_group_label>HepB + Penta batch 1</arm_group_label>
    <other_name>Hep B + DTP-HB-Hib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hep B + Pentabio (registered)</intervention_name>
    <description>1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)</description>
    <arm_group_label>Hep B + Pentabio (registered)</arm_group_label>
    <other_name>Recombinant Hepatitis B (Bio Farma) + Pentabio (Bio Farma)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, full term, newborns infants.

          -  Infant born after 37-42 weeks of pregnancy.

          -  Infant weighing 2500 gram or more at birth.

          -  Father, mother or legally acceptable representative properly informed about the study
             and having signed the informed consent form.

          -  Parents will commit themselves to comply with the indications of the investigator and
             with the schedule of the trial.

        Exclusion Criteria:

          -  Child concomitantly enrolled or scheduled to be enrolled in another trial.

          -  Mother with HBsAg positive.

          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature &gt;37.5C on Day 0).

          -  Suspected of allergy to any component of the vaccines (e.g. formaldehyde).

          -  Suspected of uncontrolled coagulopathy or blood disorders contraindicating
             intramuscular injection.

          -  Newborn suspected of congenital or acquired immunodeficiency (including HIV
             infection).

          -  Received or plans to receive any treatment likely to alter the immune response
             (intravenous immunoglobulins, blood-derived products or long term corticotherapy (&gt; 2
             weeks)).

          -  Received other vaccination with the exception of BCG and poliomyelitis.

          -  Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddy Fadliyana</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasan Sadikin General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novilia Sjafri Bachtiar</last_name>
    <phone>62222033755</phone>
    <email>novilia@biofarma.co.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mita Puspita</last_name>
    <phone>62222033755</phone>
    <email>mita.puspita@biofarma.co.id</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Garuda Primary Health Centre</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibrahim Adjie Primary Health Centre</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puter Primary Health Care</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

